Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker

医学 利尿剂 噻嗪 内科学 心力衰竭 钙通道阻滞剂 血管紧张素转换酶抑制剂 随机对照试验 临床终点 冠状动脉疾病 心脏病学 血管紧张素转换酶 血压
作者
José‐Miguel Yamal,J. Alfredo Martínez,Mikala C. Osani,Xianglin L. Du,Lara M. Simpson,Barry R. Davis
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (12): e2344998-e2344998
标识
DOI:10.1001/jamanetworkopen.2023.44998
摘要

Importance The long-term relative risk of antihypertensive treatments with regard to mortality and morbidity is not well understood. Objective To determine the long-term posttrial risk of primary and secondary outcomes among trial participants who were randomized to either a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor with up to 23 years of follow-up. Design, Setting, and Participants This prespecified secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a multicenter randomized, double-blind, active-controlled clinical trial, followed up with participants aged 55 years or older with a diagnosis of hypertension and at least 1 other coronary heart disease risk factor for up to 23 years, from February 23, 1994, to December 31, 2017. Trial participants were linked with administrative databases for posttrial mortality (N = 32 804) and morbidity outcomes (n = 22 754). Statistical analysis was performed from January 2022 to October 2023. Interventions Participants were randomly assigned to receive a thiazide-type diuretic (n = 15 002), a CCB (n = 8898), or an ACE inhibitor (n = 8904) for planned in-trial follow-up of approximately 4 to 8 years and posttrial passive follow-up for up to 23 years. Main Outcomes and Measures The primary end point was mortality due to cardiovascular disease (CVD). Secondary outcomes included all-cause mortality, combined fatal and nonfatal (morbidity) CVD, and both mortality and morbidity for coronary heart disease, stroke, heart failure, end-stage renal disease, and cancer. Results A total of 32 804 participants (mean [SD] age, 66.9 [7.7] years; 17 411 men [53.1%]; and 11 772 Black participants [35.9%]) were followed up for all-cause mortality and a subgroup of 22 754 participants (mean [SD] age, 68.7 [7.2] years; 12 772 women [56.1%]; and 8199 Black participants [36.0%]) were followed up for fatal or nonfatal CVD through 2017 (mean [SD] follow-up, 13.7 [6.7] years; maximum follow-up, 23.9 years). Cardiovascular disease mortality rates per 100 persons were 23.7, 21.6, and 23.8 in the diuretic, CCB, and ACE inhibitor groups, respectively, at 23 years after randomization (adjusted hazard ratio [AHR], 0.97 [95% CI, 0.89-1.05] for CCB vs diuretic; AHR, 1.06 [95% CI, 0.97-1.15] for ACE inhibitor vs diuretic). The long-term risks of most secondary outcomes were similar among the 3 groups. Compared with the diuretic group, the ACE inhibitor group had a 19% increased risk of stroke mortality (AHR, 1.19 [95% CI, 1.03-1.37]) and an 11% increased risk of combined fatal and nonfatal hospitalized stroke (AHR, 1.11 [95% CI, 1.03-1.20]). Conclusions and Relevance In this secondary analysis of a randomized clinical trial in an adult population with hypertension and coronary heart disease risk factors, CVD mortality was similar between all 3 groups. ACE inhibitors increased the risk of stroke outcomes by 11% compared with diuretics, and this effect persisted well beyond the trial period. Trial Registration ClinicalTrials.gov Identifier: NCT00000542
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沉默采波完成签到 ,获得积分10
2秒前
千秋完成签到 ,获得积分10
14秒前
oracl完成签到 ,获得积分10
15秒前
康康XY完成签到 ,获得积分10
16秒前
重重重飞发布了新的文献求助10
16秒前
丫丫完成签到 ,获得积分10
16秒前
奋斗的妙海完成签到 ,获得积分0
23秒前
勤恳的雪卉完成签到,获得积分10
24秒前
美满的皮卡丘完成签到 ,获得积分10
33秒前
最美夕阳红完成签到,获得积分10
40秒前
六等于三二一完成签到 ,获得积分10
41秒前
wujiwuhui完成签到 ,获得积分10
44秒前
isedu完成签到,获得积分10
46秒前
叶痕TNT完成签到 ,获得积分10
47秒前
斜玉完成签到,获得积分10
47秒前
21GolDiamond完成签到,获得积分10
47秒前
鞑靼完成签到 ,获得积分10
51秒前
邵翎365完成签到,获得积分10
58秒前
zenabia完成签到 ,获得积分10
58秒前
闪闪的谷梦完成签到 ,获得积分10
1分钟前
21完成签到 ,获得积分10
1分钟前
俊逸吐司完成签到 ,获得积分10
1分钟前
twelveyears完成签到 ,获得积分10
1分钟前
风起枫落完成签到 ,获得积分10
1分钟前
wenhuanwenxian完成签到 ,获得积分10
1分钟前
jiayoujijin完成签到 ,获得积分10
1分钟前
Dingz完成签到,获得积分10
1分钟前
kumo完成签到 ,获得积分10
1分钟前
十七完成签到 ,获得积分10
1分钟前
求知若渴口好干完成签到 ,获得积分10
1分钟前
yinhe完成签到 ,获得积分10
1分钟前
无极2023完成签到 ,获得积分10
1分钟前
huangzsdy完成签到,获得积分10
2分钟前
微卫星不稳定完成签到 ,获得积分0
2分钟前
水星完成签到 ,获得积分10
2分钟前
客官们帮帮忙完成签到 ,获得积分10
2分钟前
loren313完成签到,获得积分0
2分钟前
陈大侠完成签到 ,获得积分10
2分钟前
jue完成签到 ,获得积分10
2分钟前
拉长的诗蕊完成签到,获得积分10
2分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099800
求助须知:如何正确求助?哪些是违规求助? 2751277
关于积分的说明 7612198
捐赠科研通 2403062
什么是DOI,文献DOI怎么找? 1275162
科研通“疑难数据库(出版商)”最低求助积分说明 616276
版权声明 599053